Evidence map›Paper›PMID 35794985›Full record

ArticleJournal of oncology2022

Neferine Exerts Ferroptosis-Inducing Effect and Antitumor Effect on Thyroid Cancer through Nrf2/HO-1/NQO1 Inhibition.

Shujing Li, Yanyan Zhang, Jin Zhang, Bo Yu, Weiran Wang, Baosong Jia, Jingtao Chang, Jing Liu

Open access · hybridAbstract read
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Mechanistic insights into ferroptosis in thyroid cancer and its therapeutic implications.Apoptosis : an international journal on programmed cell death · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Frontiers in oncology · 2025
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shujing LiDepartment of Thyroid Surgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Yanyan ZhangDepartment of General Surgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Jin ZhangDepartment of Thyroid Surgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Bo YuDepartment of Thyroid Surgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Weiran WangDepartment of General Surgery, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Baosong JiaDepartment of General Surgery, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Jingtao ChangDepartment of General Surgery, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Jing LiuDepartment of Thyroid Surgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China.ORCID https://orcid.org/0000-0002-2093-325X
Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer is the most prevalent endocrine malignancy with an increasing incidence in the past few decades. Neferine possesses various pharmacological activities, which have been applied in diverse disease models, including various tumors. However, the detailed effect and mechanism of neferine on thyroid cancer are still unclear. In the current study, the viability of IHH-4 and CAL-62 cells was examined by the CCK-8 assay. The effect of neferine on the proliferation, apoptosis, invasion, vascular endothelial growth factor (VEGF), epithelial-mesenchymal transition (EMT), and ferroptosis was evaluated by CCK-8, flow cytometry, western blot, and spectrophotometry assays. Mechanically, the expressions levels of Nrf2/HO-1/NQO1 signaling were first determined by a western blot, which was then verified by Nrf2 overexpression.

Identifiers

PMID35794985
PMCPMC9252705
OpenAlexW4283579861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.